Plavix
Product Images NDC 67046-604

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 67046-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 01)

Chemical structure of clopidogrel hydrogen sulfate, the active ingredient in Plavix, showing the molecular arrangement with a thiophene ring, piperidine ring, chlorophenyl group, and sulfate component (H2SO4).*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 02)

A line graph showing cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up comparing Plavix (+ aspirin) versus placebo (+ aspirin). The graph depicts lower event rates for Plavix (+ aspirin) compared to placebo (+ aspirin). The x-axis represents months of follow-up (0 to 12), and the y-axis shows cumulative event rate percentage (0 to 16%). A p-value of 0.00009 is noted.*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 03)

A forest plot chart depicting the percent events for PLAVIX (+aspirin) versus placebo (+aspirin) across various baseline characteristics and concomitant medication therapies. It includes hazard ratios with 95% confidence intervals visualized by squares and horizontal lines, comparing the effectiveness of PLAVIX and placebo in different subgroups.*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 04)

A Kaplan-Meier survival curve showing percentage of deaths before first discharge over 28 days since randomization. The graph compares two groups: one receiving placebo and the other receiving clopidogrel, with annotations indicating 1845 deaths (8.1%) for placebo and 1726 deaths (7.5%) for clopidogrel, and noting a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 05)

A Kaplan-Meier curve chart showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. It compares outcomes between placebo and Clopidogrel groups, indicating a 9% proportional risk reduction with Clopidogrel (p = 0.002).*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 06)

A forest plot chart illustrating the odds ratios and confidence intervals for clinical events comparing Clopidogrel versus placebo across various baseline categories including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The chart includes event percentages for each group and tests for heterogeneity and proportional risk reduction.*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 07)

A forest plot chart presenting events (%) and odds ratios with confidence intervals comparing Clopidogrel and placebo groups across different categories such as Killip class, previous myocardial infarction (MI), and infarct location. The chart indicates proportional reduction statistics and global heterogeneity test results for Clopidogrel versus placebo outcomes.*

FDA Label Image

Figure (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 08)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up, comparing Plavix and Aspirin. The x-axis shows months of follow-up from 0 to 36, and the y-axis shows cumulative event rate from 0% to 16%. Two lines represent the event rates for Aspirin and Plavix, with a noted p-value of 0.045.*

FDA Label Image

Blister Of 30 Tablets (E5a90643 3f0e 45a2 A9a4 65229c38d6ab 09)

Plavix 75 mg tablet packaging label featuring a 30-count bubble pack layout. The label includes storage information, barcode, lot number, and expiration date. Packaged by Contract Pharmacy Services-PA with address details provided. Multiple numbered pill compartments are shown for daily medication tracking.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.